Rouleau J L, Chuck L H, Hollosi G, Kidd P, Sievers R E, Wikman-Coffelt J, Parmley W W
Circ Res. 1982 Mar;50(3):405-12. doi: 10.1161/01.res.50.3.405.
We attempted to alter the inherited myocardial damage and loss of contractility of the cardiomyopathic Syrian hamster (strain U-MX7-1) by giving cardiac drugs that altered intracellular calcium and myocardial workload. Thirty-seven 21-day-old cardiomyopathic and thirty-seven 21-day-old normal hamsters were divided into five groups each: verapamil-, propranolol-, digoxin-, hydralazine-, and saline-injected. On their 90th day of life, the hamsters were killed. Of the five cardiomyopathic groups, only verapamil reduced myocardial damage. When both "control" and cardiomyopathic hamsters were treated with saline, digoxin, or propranolol, the cardiomyopathic hamsters had significantly less contractile force, maximal rate of force development, and maximum velocity of unloaded shortening. When both groups were treated with verapamil or hydralazine, there were no significant group differences in the indices of contractility. However, when saline-treated cardiomyopathic hamsters were compared with drug-treated cardiomyopathic hamsters, only verapamil preserved myocardial contractility. There was also a weak correlation between the Vmax and the actin-activated ATPase activity of the cardiomyopathic hamsters (r = 0.63, P less than 0.001). We conclude that verapamil helped protect the myocardium of genetically cardiomyopathic hamsters against structural damage, and helped preserve myocardial contractility.
我们试图通过给予能改变细胞内钙和心肌工作负荷的心脏药物，来改变遗传性心肌病叙利亚仓鼠（U-MX7-1品系）的心肌损伤和收缩力丧失情况。将37只21日龄的心肌病仓鼠和37只21日龄的正常仓鼠各分为五组：分别注射维拉帕米、普萘洛尔、地高辛、肼屈嗪和生理盐水。在这些仓鼠90日龄时将其处死。在五个心肌病组中，只有维拉帕米减轻了心肌损伤。当“对照”仓鼠和心肌病仓鼠都用生理盐水、地高辛或普萘洛尔治疗时，心肌病仓鼠的收缩力、最大力量发展速率和无负荷缩短最大速度明显更低。当两组都用维拉帕米或肼屈嗪治疗时，收缩力指标没有显著的组间差异。然而，当将用生理盐水治疗的心肌病仓鼠与用药物治疗的心肌病仓鼠进行比较时，只有维拉帕米能维持心肌收缩力。在心肌病仓鼠中，最大速度（Vmax）与肌动蛋白激活的ATP酶活性之间也存在弱相关性（r = 0.63，P < 0.001）。我们得出结论，维拉帕米有助于保护遗传性心肌病仓鼠的心肌免受结构损伤，并有助于维持心肌收缩力。
